Genmab

Genmab A/S is a Danish biotechnology company founded in 1999, focused on developing innovative antibody therapeutics for cancer and other serious diseases. Headquartered in Copenhagen, Denmark, the company has significant operations in the Netherlands, the US, and Japan. Genmab went public in 2000, achieving a record DKK 1.56 billion for a European biotech IPO at that time. The company specializes in proprietary antibody-based medicines, often collaborating with global pharmaceutical partners. Notable products include EPKINLY (epcoritamab), a bispecific antibody approved in 2023 for treating relapsed or refractory diffuse large B-cell lymphoma, and Tivdak (tisotumab vedotin), an antibody-drug conjugate approved in 2021 for recurrent or metastatic cervical cancer. Genmab generates revenue through product sales, licensing agreements, and milestone payments from collaborations, serving healthcare providers and patients in need of advanced cancer therapies. Under the leadership of CEO Jan van de Winkel, Genmab continues to push the boundaries of antibody science to improve patient outcomes worldwide.